Cargando…

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma

Dysregulated metabolism is a hallmark of cancer that manifests through alterations in bioenergetic and biosynthetic pathways to enable tumor cell proliferation and survival. Tumor cells exhibit high rates of glycolysis, a phenomenon known as the Warburg effect, and an increase in glutamine consumpti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emberley, Ethan, Pan, Alison, Chen, Jason, Dang, Rosalyn, Gross, Matt, Huang, Tony, Li, Weiqun, MacKinnon, Andrew, Singh, Devansh, Sotirovska, Natalija, Steggerda, Susanne M., Wang, Tracy, Parlati, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565744/ https://www.ncbi.nlm.nih.gov/pubmed/34731180 http://dx.doi.org/10.1371/journal.pone.0259241

Ejemplares similares

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
por: Harding, James J., et al.
Publicado: (2021)

The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells
por: Wang, Diancheng, et al.
Publicado: (2016)

Identification and characterization of a novel glutaminase inhibitor
por: Cederkvist, Henning, et al.
Publicado: (2021)

Dendrimer-conjugated glutaminase inhibitor selectively targets microglial glutaminase in a mouse model of Rett syndrome
por: Khoury, Elizabeth Smith, et al.
Publicado: (2020)

T220. THE GLUTAMINASE INHIBITOR EBSELEN PREVENTS AMPHETAMINE SENSITIZATION IN MICE
por: Heffetz-Giterman, Lior, et al.
Publicado: (2018)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

Self-Assembled Micellar Glutaminase Allosteric Inhibitor for Effective Therapeutic Intervention
por: Fang, Jinzhang, et al.
Publicado: (2022)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
por: Steggerda, Susanne M., et al.
Publicado: (2017)

CD133-Functionalized Gold Nanoparticles as a Carrier Platform for Telaglenastat (CB-839) against Tumor Stem Cells
por: Poonaki, Elham, et al.
Publicado: (2022)

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
por: Thompson, Ravyn M., et al.
Publicado: (2017)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2018)

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
por: Donskov, Frede, et al.
Publicado: (2019)

The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo
por: Zou, Yun, et al.
Publicado: (2017)

PB1910: TELAGLENASTAT (CB-839) IN MONOTHERAPY AND IN COMBINATION WITH EPIGENETIC MODULATORS OR IBRUTINIB INDUCES CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
por: Jorge, Joana, et al.
Publicado: (2023)

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study
por: Schmidinger, Manuela, et al.
Publicado: (2022)

Methanodibenzo[b,f][1,5]dioxocins as Novel Glutaminase Inhibitor with Anti-Glioblastoma Potential
por: Murugesan, Akshaya, et al.
Publicado: (2023)

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
por: Timofeeva, Natalia, et al.
Publicado: (2023)

Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b(5) Activity
por: Indra, Radek, et al.
Publicado: (2020)

Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England
por: Meng, Jie, et al.
Publicado: (2018)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
por: Daud, Adil, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity
por: Liu, Hongyan, et al.
Publicado: (2021)

The Glutaminase-1 Inhibitor [(11)C-carbony]BPTES: Synthesis and Positron Emission Tomography Study in Mice
por: Zhang, Yiding, et al.
Publicado: (2023)

Inhibitors of Brassinosteroid Biosynthesis and Signal Transduction
por: Rozhon, Wilfried, et al.
Publicado: (2019)

Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer
por: Kimura, Mariko, et al.
Publicado: (2018)

mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
por: Ciołczyk-Wierzbicka, Dorota, et al.
Publicado: (2019)

mTOR inhibitor everolimus reduces invasiveness of melanoma cells
por: Ciołczyk-Wierzbicka, Dorota, et al.
Publicado: (2019)

Targeting glutaminase1 and synergizing with clinical drugs achieved more promising antitumor activity on multiple myeloma
por: Qiu, Qiang, et al.
Publicado: (2019)

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
por: Proskorovsky, Irina, et al.
Publicado: (2018)

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
por: Hage, C, et al.
Publicado: (2013)

Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model
por: Sun, Yinggang, et al.
Publicado: (2015)

Augmented Therapeutic Potential of Glutaminase Inhibitor CB839 in Glioblastoma Stem Cells Using Gold Nanoparticle Delivery
por: Giesen, Beatriz, et al.
Publicado: (2021)

New insights into the molecular mechanisms of glutaminase C inhibitors in cancer cells using serial room temperature crystallography
por: Milano, Shawn K., et al.
Publicado: (2021)

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
por: Ho, Won Jin, et al.
Publicado: (2021)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
por: Wehming, Mathis, et al.
Publicado: (2023)

Signal transduction inhibitors for the treatment of rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_k1e8hnqa6bjds43nuhk1halk3v